Project Grant W81XWH1110573

Summary: Mechanisms of ALS/FTD Determined by Multimodal Single Cell Spatial Transcriptomics The University of California, San Diego received a $3.08M Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded September 12, 2025, with a completion date of June 30, 2029. This research grant funds the development and application of a multimodal spatial...

The Project Grant award of $404,058 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to identify novel small molecules that stabilize functional, multimeric forms of the TDP43 protein. The goal is to restore TDP43's native RNA binding and splicing regulation functions, which are impaired in frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other TDP43-related neurodegenerative diseases. The research will leverage high-throughput...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $796,875 project grant to the University of Florida (UF) Division of Sponsored Research. The grant, awarded on April 1, 2024, supports the development of heterobifunctional degraders of TDP-43 as a novel therapeutic strategy for amyotrophic lateral sclerosis (ALS). Under this grant, the University of North Carolina at Chapel Hill (UNC-CH) Office of Sponsored Research is serving as a sub-awardee....

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $450,313 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to The Johns Hopkins University to develop high-throughput screening (HTS) assays to identify activators of the nemo-like kinase (NLK) protein. The goal is to find small molecule compounds that can lower mutant huntingtin (mHTT) protein levels as a potential therapeutic approach for Huntington's...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...

Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $460,625 to the University of Massachusetts Medical School on June 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support a two-year research investigation through May 31, 2027. The project, titled "Investigating the Role of TDP-43 Citrullination in ALS Pathogenesis," focuses on understanding how...

The Defense Health Agency awarded a $929,948 Project Grant to The Washington University in St. Louis, Missouri to support the research project "TARGETING TDP-43 MITOCHONDRIAL MISLOCALIZATION IN ALS". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. The research project will investigate mitochondrial...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $437,250 to the University of California, San Diego (UCSD) to conduct pooled in vivo screening of combination gene therapies for enhancing axonal regeneration after spinal cord injury (SCI). The key objectives are to 1) perform CRISPR screening to identify the most effective...

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...